
Naftol25 mg
ACI Limited
Naftopidil is indicated for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men.
Naftopidil is indicated for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men.
Naftopidil does not reduce prostate size and is not a treatment for prostate cancer; it treats urinary symptoms only.
Not indicated for use in women or in children, since benign prostatic hyperplasia is a condition specific to the male prostate gland.
| Step | Dose | Timing |
|---|---|---|
| Starting dose | 25 mg once daily | After a meal |
| Titration | Increase to 50 mg, then up to a maximum of 75 mg once daily as needed, at intervals of 1-2 weeks | After a meal |
| Maximum dose | 75 mg once daily | After a meal |
Tablets should be swallowed whole with water. Naftopidil is intended for long-term, individualized use guided by symptom response (see Duration of Treatment).
Naftopidil is not indicated in children (see Pediatric Uses).
The most commonly reported side effects of Naftopidil include:
Less commonly, orthostatic (postural) hypotension can occur, particularly after the first dose or a dose increase (see Precautions and Warnings). Report any severe dizziness, fainting, palpitations, or vision changes to your physician promptly.
Naftopidil is contraindicated in:
Naftopidil is not intended for use in women, as benign prostatic hyperplasia is a male-specific condition.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.